Key Takeaways:
- Strategic Reset: Edwards Lifesciences exited the JenaValve acquisition in January 2026, refocusing capital on internal TAVR and mitral platforms supporting long-term growth.
- Earnings Upgrade: Edwards Lifesciences raised 2026 EPS guidance to $3, reflecting margin discipline and stronger demand across structural heart procedures.
- Valuation Outlook: Based on our valuation assumptions, Edwards Lifesciences stock could reach $103 by December 2027 as revenue growth and margins normalize.
- Return Profile: This implies 27% total upside from the current $81 price, translating to roughly 13% annualized returns over the next 2 years.
Edwards Lifesciences (EW) is a global leader in structural heart devices, with strong positioning in transcatheter valve therapies across high-acuity cardiovascular procedures.
In mid-January, Edwards Lifesciences dropped the JenaValve deal after an FTC ruling, refocusing on internal pipeline execution.
Edwards Lifesciences generates roughly $6 billion in annual revenue, supported by steady procedure growth and minimally invasive valve adoption.
The company also delivers about $1 billion in profit with 29% operating margins, reflecting scale benefits and disciplined cost control.
Edwards Lifesciences trades near $81 versus a modeled $103 value, reflecting execution progress against cautious valuation.
What the Model Says for EW Stock
We analyzed Edwards Lifesciences stock using assumptions tied to TAVR scale, FDA approvals, disciplined spending, and stable capital allocation.
Based on 10.1% revenue growth, 28.7% operating margins, and a 29.3x exit multiple, the model reflects sustained structural profitability.
That framework points to a $103 target price, implying 26.5% total upside and a 13% annualized return.
Our Valuation Assumptions
TIKR’s Valuation Model lets you plug in your own assumptions for a company’s revenue growth, operating margins, and P/E multiple, and calculates the stock’s expected returns.
Here’s what we used for EW stock:
1. Revenue Growth: 10.1%
Edwards Lifesciences posted about $6 billion revenue recently, following prior softness, showing recovery tied to structural heart procedure volumes.
Current execution reflects steady TAVR demand and early mitral adoption, offset by delayed contributions after the blocked JenaValve acquisition.
Forward growth depends on Sapien platform expansion and regulatory progress, while risks include hospital budget pressure and slower procedure growth.
Consensus estimates assume 10.1% revenue growth, supporting a 13% annual return amid durable demand and regulatory constraints.
2. Operating Margins: 28.7%
Edwards Lifesciences historically sustained operating margins near 29%, reflecting premium device pricing and scale within transcatheter valve therapies.
Recent quarters show margin stability as R&D and sales spending normalize following peak investment cycles tied to pipeline expansion.
Profitability outlook rests on mix improvement and manufacturing efficiency, tempered by trial costs and competitive pricing pressure.
In line with analyst consensus projections, 28.7% operating margins reflect normalized cost discipline alongside continued investment in next-generation valve platforms.
3. Exit P/E Multiple: 29.3x
Edwards Lifesciences has traded between roughly 30x and 34x earnings over recent years, supported by predictable cash generation and clinical leadership.
Investor caution increased after the FTC ruling, limiting acquisition-led expansion and tempering near-term sentiment despite raised EPS guidance.
Valuation support requires sustained earnings growth and trial success without regulatory setbacks or pricing disruption across core valve categories.
Street consensus supports a 29.3x exit multiple, balancing execution reliability against regulatory risk and moderated growth expectations.
What Happens If Things Go Better or Worse?
Edwards Lifesciences’ outcomes depend on procedure volume recovery, clinical adoption pace, and cost discipline, setting up a range of possible paths through 2029.
- Low Case: If hospital demand stays uneven and trial costs persist, revenue grows around 8.6% with margins near 25.2% → 5.7% annualized return.
- Mid Case: With core TAVR demand steady and mitral adoption progressing, revenue growth near 9.6% and margins improving toward 27.0% → 12.1% annualized return.
- High Case: If mitral therapies scale efficiently and pricing holds, revenue reaches about 10.6% and margins approach 28.5% → 18.2% annualized return.
The $128 mid-case target price depends on volume growth and cost discipline, not multiple expansion or sentiment-driven rerating.
How Much Upside Does It Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
